^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + ceralasertib (AZD6738) (ATR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib
Published date:
01/25/2022
Excerpt:
In a BRCA2-mutant patient-derived triple-negative breast cancer (TNBC) xenograft model, complete tumor regression was achieved with 3-5 days of daily AZD6738 per week concurrent with olaparib....These preclinical data provide rationale for clinical evaluation of AZD6738 as a monotherapy or combinatorial agent.
DOI:
10.1158/0008-5472.CAN-21-2997
